Kerckhoff Heart Center, Benekestr. 2-8, 60231 Bad Nauheim, Germany.
J Invasive Cardiol. 2020 Dec;32(12):E355-E361. doi: 10.25270/jic/20.00236. Epub 2020 Nov 22.
Patients with low-flow, low-gradient (LFLG) aortic stenosis (AS) have the highest risk among all AS patients. Rapid ventricular pacing (RVP) is frequently used during transcatheter aortic valve implantation (TAVI), but may negatively impact critical left ventricular function in these patients. We investigated the effects of RVP in patients with LFLG-AS undergoing implantation of a self-expandable valve prosthesis.
In this retrospective study, patients with LFLG-AS were classified according to the number of cumulative RVP episodes.
Thirty-one patients with no episodes of RVP, 46 patients with 1 episode, and 40 patients with 2 or more episodes (2+) were identified. Society of Thoracic Surgeons (STS) scores in patients with 0, 1, or 2+ RVP episodes were 5.1% (interquartile range [IQR], 3.5%-8.9%), 6.0% (IQR, 3.8%-8.8%), and 4.8% (3.8%-8.1%), respectively. Peri-interventional adverse events tended to be highest in the group with 1 RVP. Residual aortic regurgitation was in 3.2%, 4.8%, and 2.6% (P=.87) in patients with 0, 1, and 2+ RVP episodes, respectively. Thirty-day mortality rates were 3.2%, 6.5%, and 7.5% (P=.74) and 1-year mortality rates were 22.6%, 30.4%, and 20.0% (P=.51) in patients with 0, 1, and 2+ RVP episodes, respectively. STS score, body mass index, prevalence of chronic lung disease, and more-than-mild residual aortic regurgitation emerged as independent predictors of 1-year mortality, whereas the number of RVP episodes had no impact on outcomes.
One-year mortality is not influenced by RVP, but is influenced by the individual patient's risk. The final implantation results in patients with 2+ RVP episodes suggest that RVP during implantation of self-expandable TAVI prostheses should not be withheld in an attempt to achieve optimal results, even in LFLG-AS patients.
在所有主动脉瓣狭窄(AS)患者中,低流量、低梯度(LFLG)AS 患者的风险最高。在经导管主动脉瓣植入术(TAVI)期间,常采用快速心室起搏(RVP),但可能对这些患者的关键左心室功能产生负面影响。我们研究了 RVP 对接受自膨式瓣膜假体植入的 LFLG-AS 患者的影响。
在这项回顾性研究中,根据累积 RVP 发作次数将 LFLG-AS 患者进行分类。
确定了 31 例无 RVP 发作的患者、46 例有 1 次 RVP 发作的患者和 40 例有 2 次或以上 RVP 发作(2+)的患者。0、1、2+RVP 发作的患者中,胸外科医师学会(STS)评分分别为 5.1%(四分位距 [IQR],3.5%-8.9%)、6.0%(IQR,3.8%-8.8%)和 4.8%(3.8%-8.1%)。在有 1 次 RVP 的组中,围手术期不良事件的发生率最高。在 0、1、2+RVP 发作的患者中,残余主动脉瓣反流率分别为 3.2%、4.8%和 2.6%(P=.87)。30 天死亡率分别为 3.2%、6.5%和 7.5%(P=.74),1 年死亡率分别为 22.6%、30.4%和 20.0%(P=.51)。STS 评分、体重指数、慢性肺部疾病患病率和中重度残余主动脉瓣反流是 1 年死亡率的独立预测因素,而 RVP 发作次数对结果无影响。
1 年死亡率不受 RVP 影响,而是受患者个体风险影响。在有 2+RVP 发作的患者中,最终的植入结果表明,在植入自膨式 TAVI 假体时不应为了获得最佳结果而避免 RVP,即使在 LFLG-AS 患者中也是如此。